Product Availability Update

Promega Manufacturing and Delivery Systems continue to be fully operational during the COVID-19 outbreak. Our teams are in regular contact with suppliers and distributors worldwide and are taking all steps necessary to address both demands for diagnostic tools and reliable delivery of all products as quickly as possible. Learn more

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Expanding Applications of Bioluminescence Technology Predictive Bioassays for TNFa Biologicals Potency and Dose-Standardization Studies

Sarah Shultz, Andrew Niles, Jey Cheng and Simon T.M. Allard
Promega Corporation
Publication Date: 2008

Abstract

Simple and predictive bioassays for potency and dose-standardization are still sought by the biopharmaceutical industry. Automatable, homogeneous bioassays are desirable because they can help to streamline this evaluative process. Implementing straightforward predictive automation-friendly bioassays as demonstrated in this article allows effective assessment of anti-TNFa and likely other biologicals for quality control. This article was reprinted in Promega Notes 100 with permission from Genetic Engineering News.

Promega Notes 100, 19–21.